[{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Altasciences Company Inc \/ Alladapt Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Altasciences Company Inc \/ Alladapt Immunotherapeutics"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Qbeco","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ceapro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Undisclosed"},{"orgOrder":0,"company":"Ceapro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Undisclosed"}]